Levosimendan Stada

Levosimendan, the active ingredient in Levosimendan Stada, is a calcium sensitizer / potassium channel opener presented as an intravenous solution for intravenous use. By increasing the sensitivity of troponin C to calcium and causing vasodilation through ATP‑sensitive potassium channel activation, it helps restore hemodynamic stability in severe heart‑failure episodes.

GNH USA supplies Levosimendan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of acute heart failure and related low‑output states.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. Cardiogenic shock: provides inotropic support when conventional agents are insufficient. Post‑cardiac surgery low cardiac output syndrome: helps maintain hemodynamic stability during recovery. Severe chronic heart failure awaiting transplant: used as bridge therapy to improve functional status.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: mild to moderate drop in blood pressure, often transient. - Headache: dull or throbbing pain, usually resolves without intervention. - Nausea: occasional upset stomach, may be alleviated with anti‑emetics. - Tachycardia: modest increase in heart rate, monitored during infusion.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure fall requiring vasopressor support. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced coronary perfusion leading to chest discomfort. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Levosimendan requires careful monitoring and specific precautions to ensure patient safety. - Cardiovascular monitoring: continuous blood pressure and ECG observation during infusion. - Renal function: assess renal impairment before initiation and adjust therapy as needed. - Electrolyte balance: correct potassium and magnesium abnormalities to reduce arrhythmia risk. - Concomitant vasodilators: use with caution as additive hypotensive effects may occur. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Other inotropes (e.g., dopamine, dobutamine): increase risk of arrhythmias. - Strong CYP450 inhibitors (e.g., ketoconazole): can raise plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired hemodynamic response. - Diuretics: can exacerbate electrolyte disturbances. - ACE inhibitors or ARBs: additive hypotensive effect may require dose adjustment.